Page 35 - Read Online

Pellerino et al. J Cancer Metastasis Treat 2020;6:41 I http://dx.doi.org/10.20517/2394-4722.2020.80 Page 17 of 20

patients with neoplastic meningitis. Fluid Barriers CNS 2017;14:22.
41. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, et al. Genomic characterization of brain metastases reveals branched
evolution and potential therapeutic targets. Cancer Discov 2015;5:1164-77.
42. Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, et al. Genomic characterization of human brain metastases identifies drivers of
metastatic lung adenocarcinoma. Nat Genet 2020;52:371-7.
43. Nanjo S, Arai S, Wang W, Takeuchi S, Yamada T, et al. MET copy number gain is associated with gefitinib resistance in leptomeningeal
carcinomatosis of EGFR-mutant lung cancer cells. Mol Cancer Ther 2017;16:506-15.
44. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, et al. Novel D761Y and common secondary T790M mutations in epidermal growth
factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-501.
45. Ohara S, Ushijima T, Gunji I, Tanai C, Tanaka Y, et al. Brain metastasis effectively treated with erlotinib following the acquisition of
resistance to gefitinib: a case report. J Med Case Rep 2014;8:64.
46. Fan Y, Hu M, Zhu X, Wang M, Xu Y, et al. Exploration of the underlying mechanisms of leptomeningeal metastasis in NSCLC patients
through NGS of cerebrospinal fluid. J Thorac Oncol 2017;12:S271.
47. Jiang BY, Li Y, Chuai S, et al. NGS to reveal heterogeneity between cerebrospinal fluid and plasma ctDNA among non-small cell lung
cancer patients with leptomeningeal carcinomatosis. Proc Am Soc Clin Oncol 2017;35:9022.
48. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant
lung cancer: distinct natural history of patients with tumor harboring the T790M mutation. Clin Cancer Res 2011;17:1616-22.
49. Lombardi G, Zustovich F, Farina P, Puppa AD, Manara R, et al. Neoplastic meningitis from solid tumors: new diagnostic and therapeutic
approaches. Oncologist 2011;16:1175-88.
50. Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, et al. The neurologic assessment in neuro-oncology (NANO) scale:
a tool to assess neurologic function for integration into the response assessment in neuro-oncology (RANO) criteria. Neuro Oncol
2017;19:625-35.
51. Mason W. NANO, a practical scale for neurologic assessments in patients with brain tumors? Neuro Oncol 2017;19:603-4.
52. Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, et al. Leptomeningeal metastases: a RANO proposal for response criteria.
Neuro Oncol 2017;19:484-92.
53. Chamberlain M, Soffietti R, Raizer J, Rudà R, Brandsma D, et al. Leptomeningeal metastasis: a response assessment in neuro-oncology
critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol 2014;16:1176-85.
54. Singh SK, Leeds NE, Ginsber LE. MR imaging of leptomeningeal metastases: comparison of three sequences. AJNR Am J Neuroradiol
2002;23:817-21.
55. Chamberlain MC. Comprehensive neuraxis imaging in leptomeningeal metastasis: a retrospective case series. CNS Oncol 2013;2:121-8.
56. Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, et al. The RANO leptomeningeal metastasis group proposal to assess response
to treatment: lack of feasibility and clinical utility and a revised proposal. Neuro Oncol 2019;21:648-58.
57. Le Rhun E, Weller M, Brandsma D, Van den B, de Azambuja H, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol 2017;28:iv84-99.
58. Hyun JW, Jeong IH, Joung A, Cho HJ, Kim SH, et al. Leptomeningeal metastasis: clinical experience of 519 cases. Eur J Cancer
2016;56:107-14.
59. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann
Neurol 1995;38:51-7.
60. Komori T, Delbeke D. Leptomeningeal carcinomatosis and intramedullary spinal cord metastases from lung cancer: detection with FDG
positron emission tomography. Clin Nucl Med 2001;26:905-7.
61. Lee SJ, Lee JI, Nam DH, Ahn YC, Han JH, et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on
survival and correlated prognostic factors. J Thorac Oncol 2013;8:185-91.
62. Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, et al. Liquid biopsy in central nervous system metastases: a RANO
review and proposals for clinical applications. Neuro Oncol 2019;21:571-84.
63. van Bussel MTJ, Pluim D, Milojkovic Kerklaan B, Bol M, Sikorska K, et al. Circulating epithelial tumor cell analysis in CSF in patients
with leptomeningeal metastases. Neurology 2020;94:e521-8.
64. Jiang BY, Li YS, Guo WB, Zhang XC, Chen ZH, et al. Detection of driver and resistance mutations in leptomeningeal metastases of
NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells. Clin Cancer Res 2017;23:5480-8.
65. Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, et al. Rare cell capture technology for the diagnosis of leptomeningeal
metastasis in solid tumors. Neurology 2013;80;1598-605.
66. Tu Q, Wu X, Le Rhun E, Blonski M, Wittwer B, et al. CellSearch technology applied to the detection and quantification of tumor cells in
CSF of patients with lung cancer leptomeningeal metastasis. Lung Cancer 2015;90:352-7.
67. Sasaki S, Yoshioka Y, Ko R, Katsura Y, Namba Y, et al. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for
leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefinitib therapy failure.
Respir Investig 2016;54:14-9.
68. Zheng MM, Li YS, Jiang BY, Tu HY, Tang WF, et al. Clinical utility of cerebrospinal fluid cell-free DNA as liquid biopsy for
leptomeningeal metastases in ALK-rearranged NSCLC. J Thorac Oncol 2019;14:924-32.
69. Ying S, Ke H, Ding Y, Liu Y, Tang X, et al. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non small cell
lung cancer patients with leptomeningeal metastases. Cancer Biol Ther 2019;20:562-70.
70. Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance